



Update regarding Hemlibra® (emicizumab injection): Introduction of Transfer Needle with Filter

February 16, 2021

Dear Healthcare Professional,

We are writing to notify you following a recent communication regarding a pending application for the use of a filter transfer needle for use with Hemlibra® (emicizumab injection).

We are pleased to inform you that as of January 21, 2021, Health Canada has updated the HEMLIBRA Product Monograph to include the use of a filtered transfer needle for withdrawing medication from HEMLIBRA vials prior to subcutaneous injection. We are currently working to establish timelines on availability of new convenience kits (injection kits) which will contain the filter needle. We anticipate these to be available early March 2021. All previously distributed convenience kits may be used as usual, as this is a technical change and doesn't impact the safety or efficacy of HEMLIBRA. Note that HEMLIBRA vials continue to be distributed separately from the kits and they are not combined together.

The use of a transfer needle with a filter for the administration of HEMLIBRA does not change the current prescribing method of the medicine. Patients are advised to consult their physician for further information regarding this recent update to the HEMLIBRA Product Monograph.

The risk/benefit profile of HEMLIBRA remains unchanged. Our priority remains to deliver the highest quality medicines and the transfer filter needle provides additional confidence for patients and Healthcare professionals in the use of HEMLIBRA.

Should you have any additional questions, please contact a member of the Roche Canada Medical Information team:

Email: mississauga.canada_medinfo@roche.com

Tel.: 1-888-762-4388

Fax.: 1-905-542-5610

Sincerely,

Paul Bloomfield
Manager, Quality Management
Hoffmann-La Roche Limited
7070 Mississauga Road
Mississauga, ON L5N 5M8 Canada